FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 517 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Cancer Research UK’s charity Christmas cards now available October 28, 2021 Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... April 28, 2025 ESMO Releases New Patient Guide in Hepatocellular Carcinoma June 30, 2020 Load more HOT NEWS Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic... Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma... Patients with Early Stage NSCLC Have a Higher TMB in Comparison... Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’
